When Muscle’s Hidden Helpers Die, Inflammation Devours Muscle From Within

Skeletal muscle is not just a passive bundle of contractile fibers. It is a living ecosystem, packed with resident support cells that quietly keep the tissue healthy. Among the most important of these are fibro-adipogenic progenitors, or FAPs, a population of stromal cells that makes up between 5 and 15 percent of the nuclei in skeletal muscle. For years, scientists have known that removing these cells causes muscles to waste away with alarming speed, but the mechanism behind that collapse remained stubbornly obscure. Now, a study published in the Journal of Cachexia, Sarcopenia and Muscle offers a striking answer: it is not the absence of the FAPs themselves that destroys muscle, but the inflammatory storm unleashed by their death.

The research team, working at the University of Florida, engineered mice in which FAPs could be selectively eliminated at will. They crossed animals carrying a tamoxifen-activated Cre recombinase driven by the Pdgfra promoter, which is active in FAPs, with mice carrying a diphtheria toxin A gene inserted into the Rosa26 locus. When adult mice, aged twelve to thirteen weeks, received five consecutive daily injections of tamoxifen, the toxin switched on inside FAPs and killed them. Three weeks later, the researchers found that FAP abundance in the muscle had plummeted by roughly 90 percent. The consequences were dramatic and systemic: total body mass and lean mass fell in both males and females, hindlimb muscles including the tibialis anterior, extensor digitorum longus and soleus shrank significantly, and even the spleen, liver and inguinal fat pads lost substantial weight, shrinking by up to 30 percent.

Crucially, the atrophy was not selective. Because the three muscles examined span a range of metabolic and contractile properties, the wasting appeared to be entirely independent of fiber type. Yet when the team tested muscle function directly, a surprising picture emerged. Absolute maximum isometric force was significantly reduced in both fast-twitch and slow-twitch muscles of the FAP-depleted mice, exactly as expected from smaller muscles. But when force was normalized to the muscle’s reduced cross-sectional area, the so-called specific force was completely unchanged. The contractile machinery inside each fiber was working perfectly fine. Even eccentric contractions, which subject muscles to damaging lengthening forces, revealed no increase in fragility. In other words, the muscle was losing quantity, not quality.

One long-standing hypothesis held that FAPs keep muscle healthy by supporting the neuromuscular junction, the synapse where nerves command fibers to contract. FAPs do cluster physically around these junctions, and previous work had suggested their deletion triggers synaptic degeneration and denervation-like atrophy. To test this rigorously, the researchers performed whole-mount immunofluorescence on the junctions of the EDL and soleus muscles, labeling presynaptic nerve terminals with antibodies against neurofilament and synaptic vesicle proteins, and postsynaptic acetylcholine receptors with fluorescently tagged alpha-bungarotoxin. The result was unambiguous: complete overlap between pre- and postsynaptic structures, intact endplate gutters, no fragmentation, and normal terminal Schwann cell morphology. Functional testing told the same story. When the team compared force produced by direct muscle stimulation against force evoked through the nerve, the ratios were equivalent in control and FAP-depleted mice, indicating flawless synaptic transmission. Molecular markers of denervation, such as shifts in acetylcholine receptor subunit genes, were also absent.

With the neuromuscular hypothesis ruled out for this acute setting, the team turned to the timeline of the wasting itself. Longitudinal body composition measurements revealed that most of the lean mass loss occurred during the active tamoxifen dosing window, not during the weeks of washout that followed. Apoptotic FAPs, identified by cleaved caspase 3 staining, were detectable as early as one day after the first injection. By day three, FAP numbers had collapsed. And by day five, the muscle was flooded with innate immune cells: myeloperoxidase-positive neutrophils and CD68-positive macrophages arrived in a massive, synchronized wave. The temporal sequence was telling. Cell death came first, immune infiltration followed, and only then did the muscle begin to visibly shrink.

Transcriptional profiling filled in the molecular plot. The researchers tracked two families of genes over time: atrogenes, which include the E3 ubiquitin ligases Trim63 and Fbxo32 and the autophagy markers Ulk1 and Sqstm1, and inflammatory chemokines and cytokines. An early spike in atrogene expression at day one occurred in both control and experimental mice and was attributed to the stress of tamoxifen treatment itself. But at day five, only the FAP-depleted muscles mounted a second, powerful surge of proteolytic gene expression. Preceding that surge, chemokine expression exploded. Ccl2, Ccl12, Cxcl1 and Cxcl2 rose fifty- to one-hundred-fold above control levels, peaking at day three, precisely before the atrogene wave. Interleukin-6, a cytokine with well-established links to muscle catabolism, climbed roughly fifteen-fold and stayed elevated. Notably, circulating IL-6 rose only modestly, showing that this was a fiercely local inflammatory response rather than a systemic one, and the entire transcriptional storm resolved by day twenty-eight, marking the atrophy as acute rather than chronic.

The most counterintuitive finding came when the researchers removed the immune cells themselves. Using clodronate liposomes to deplete macrophages and an anti-Ly6G antibody to eliminate neutrophils, they tested whether the infiltrating cells were culprits or protectors. The answer was neither simple nor expected: depleting either population, or both simultaneously, made the muscle wasting significantly worse. Even control mice with fully intact FAPs lost muscle when their myeloid cells were cleared. Macrophage depletion blunted the expression of Ccl2 and Ccl12, identifying macrophages as a likely source of those chemokines, yet this reduction failed to rescue muscle mass or fiber size. Neutrophil depletion, meanwhile, pushed Cxcl1 and Cxcl2 even higher, correlating with heightened atrogene expression and more severe atrophy. The infiltrating immune cells, it seems, perform essential housekeeping, clearing debris from the dying progenitors and resolving tissue stress, and their absence leaves the muscle more vulnerable, not less.

If the cells were not the problem, perhaps their signaling was. The team turned to pharmacology, treating mice with either SB225002, a selective antagonist of the CXCR2 receptor through which CXCL1 and CXCL2 act, or VBP15, also known as vamorolone, a dissociative anti-inflammatory steroid that inhibits the NF-kappa-B pathway, a central transcriptional regulator of wasting programs. Both interventions produced striking protection. Treated FAP-depleted mice retained their lean mass and fat mass, their muscles kept significantly more wet weight and fiber cross-sectional area, and their atrogene expression was substantially suppressed. Critically, immunofluorescence confirmed that neither drug changed the number of immune cells entering the tissue. The protection came from quieting inflammatory signaling, not from blocking infiltration. The two drugs also worked through distinguishable mechanisms: vamorolone broadly suppressed chemokine expression, while CXCR2 blockade triggered a compensatory rise in CXCL1 and CXCL2, a classic feedback loop when ligands can no longer engage their receptor.

The study’s authors are careful about what these results do and do not prove. Because eliminating FAPs necessarily involves killing them, the design cannot fully separate the loss of FAP-derived trophic support from the consequences of cell death itself. The transient drop in muscle Igf1 expression and the modest rise in myostatin hint that trophic factors may contribute, yet previous work showing that deleting Igf1 specifically from FAPs does not shrink muscle argues against trophic loss as the primary driver. The authors suggest that the early atrophy reflects the inflammatory fallout of progenitor death rather than evidence that FAPs actively protect muscle mass under normal conditions, though they acknowledge that other FAP-derived factors likely matter for long-term homeostasis, particularly given that transplanting FAPs back into muscle partially rescues the atrophy.

The implications reach well beyond this mouse model. Inflammation has long been recognized as a driver of muscle wasting in cancer cachexia, sarcopenia and chronic disease, and therapies that blunt inflammatory signaling are actively pursued. This study adds a crucial nuance: the same immune cells can be simultaneously protective and destructive, depending on whether one removes the cells or modulates their signals. Physical depletion of myeloid populations worsened wasting, while receptor-level and transcriptional modulation of their inflammatory output preserved muscle. For clinicians and drug developers, the lesson is that the target is not the inflammatory cells themselves but the molecular conversations they conduct, particularly the CXCL1/2-CXCR2 axis and the NF-kappa-B pathway it feeds. As the population ages and muscle wasting syndromes impose enormous clinical burdens, understanding how the death of a single supporting cell type can ignite a self-sustaining cycle of inflammation and proteolysis may prove to be one of the most consequential insights in muscle biology.

Subject of Research: Mechanisms of inflammation-mediated skeletal muscle atrophy following fibro-adipogenic progenitor ablation in mice

Article Title: Fibro‐Adipogenic Progenitor Ablation Triggers Muscle Atrophy Through Cell Death‐Induced Inflammation

Article References: Luo, Y. E., Lee, Y. I., Abe‐Teh, Z., Young, R. Y., Wei‐LaPierre, L., & Barton, E. R. (2026). Fibro‐Adipogenic Progenitor Ablation Triggers Muscle Atrophy Through Cell Death‐Induced Inflammation. Journal of Cachexia, Sarcopenia and Muscle, 17(5), Article e70393. https://doi.org/10.1002/jcsm.70393

Image Credits: AI Generated

DOI: 10.1002/jcsm.70393

Keywords: fibro-adipogenic progenitors, skeletal muscle atrophy, inflammation, CXCR2, NF-kappa-B, neuromuscular junction, macrophages, neutrophils, cachexia, sarcopenia, chemokines, vamorolone